SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

SELLAS Life Sciences Group Inc.

Global Surfaces Limited ( ($IN:GSLSU) ) has issued an announcement. Global Surfaces Limited’s board has approved the audited standalone and consoli...

Global Surfaces clears FY26 results, reshapes board roles and governance agenda

Maxim Group analyst Tate Sullivan maintained a Hold rating on Solaris Resources yesterday and set a price target of $11.48. Sullivan covers the Ind...

Solaris Resources (SLSR) Receives a Hold from Maxim Group

An update from Solaris Resources ( ($TSE:SLS) ) is now available. Solaris Resources Inc. has filed its Form 6-K for May 2026, furnishing unaudited ...

Solaris Resources Files Q1 2026 Results, Shows Narrower Loss but Deepening Shareholder Deficit

Solstice Minerals Limited ( ($AU:SLS) ) just unveiled an announcement. Solstice Minerals has called a general meeting of shareholders to be held in...

Current Quarter	$NA	Next Quarter	$NA
Current Year	$NA	Next Year	$NA
QoQ Growth	NaN%	YoY Growth	NaN%
3Y EPS CAGR	+51.0%	Target Price	$10.00
Consensus	Buy	Upside	+16.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLS	$8.58	+5.67%	9.16M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLS	$8.58	+5.7%	9.16M
3
4
5
6

SLS

SLS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get SELLAS Life Sciences Group Inc. Data in Excel

Get SELLAS Life Sciences Group Inc. Data in Excel